Nobivac 1-RabiesThis page contains information on Nobivac 1-Rabies for veterinary use.
The information provided typically includes the following:
- Nobivac 1-Rabies Indications
- Warnings and cautions for Nobivac 1-Rabies
- Direction and dosage information for Nobivac 1-Rabies
Nobivac 1-RabiesThis treatment applies to the following species:
Annual Revaccination: Dogs and Cats
Restricted to use by or under the direction of a licensed veterinarian.
IN THE ABSENCE OF A VETERINARIAN-CLIENT-PATIENT RELATIONSHIP, FEDERAL REGULATIONS PROHIBIT THE RELABELING, REPACKAGING, RESALE, OR REDISTRIBUTION OF THE INDIVIDUAL CONTENTS OF THIS PACKAGE.
DIRECTIONS FOR USE - PLEASE READ CAREFULLY
FOR ANIMAL USE ONLY
Nobivac® 1-Rabies vaccine is for vaccination of healthy dogs and cats as an aid in preventing rabies. The vaccine is prepared from cell-culture-grown, chemically-inactivated rabies virus. The seed virus is a highly immunogenic, fixed strain of rabies virus which originated from Louis Pasteur’s original isolate in 1882. The inactivated virus is formulated with a highly purified adjuvant and is packaged in liquid form.
Rabies is a worldwide, high mortality disease affecting mammalian species. Wild animals are common vectors of the disease and the major source of transmission to humans and domestic animals. Despite successful attempts over the years to reduce the incidence of rabies, recent published reports indicate that in the U.S. more than 30,000 people undergo treatment every year for possible exposure.1 Domestic animals are the major source of exposure for humans. Since 1980, the most commonly reported rabid domestic animals have been cats, cattle and dogs. In 1990, a total of 4,881 cases of animal rabies were reported to the Center for Disease Control by all 50 states, the District of Columbia and Puerto Rico.2 Susceptibility to rabies varies according to pet species. Rabies is not a treatable disease and suspect pets are usually quarantined until a clinical diagnosis is made, at which time they are destroyed.
The route of infection can be oral, respiratory, or parenteral. Following infection, a paralytic syndrome ensues, emerging as either the “furious” or “dumb” form. “Furious rabies” is characterized by unusual aggression; “dumb rabies” by lethargy and a desire to avoid contact. Respiratory failure is the immediate cause of death.
Safety And Efficacy
Because Nobivac 1-Rabies vaccine is produced on an established cell line, it has safety advantages over inactivated brain-origin rabies vaccines. Tissue-origin vaccines contain extraneous protein in addition to rabies antigen that can lead to autoimmune disease.
The established cell line used in Nobivac 1-Rabies has been extensively tested for freedom from contaminating agents. In addition, use of an established cell line yields a vaccine of consistent potency from serial to serial. Nobivac 1-Rabies has proven to be uniformly safe in experimental tests and no significant adverse reactions were reported in extensive clinical trials of the vaccine.
A duration of immunity study, conducted in accordance with federal regulation and under U.S. Department of Agriculture direction, demonstrated that a 1 mL dose met federal guidelines for protection of dogs and cats against virulent challenge administered more than a year after vaccination.
1. Store at 2°-7°C (35°-45°F). Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
2. Use entire contents when first opened.
3. Sterilized syringes and needles should be used to administer this vaccine.
4. Contains gentamicin as preservative.
5. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
6. This product has been tested under laboratory conditions and shown to meet all Federal Standards for safety and ability to immunize normal healthy animals. This level of performance may be affected by conditions of use such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.
Following the advice of the American Veterinary Medical Association on Vaccination Principles, an appropriate revaccination program for individual animals should be made based upon veterinarian-client-patient relationships.
1. General Directions: Shake well. Aseptically administer 1 mL subcutaneously. Dogs may be vaccinated intramuscularly or subcutaneously.
2. Primary Vaccination: Healthy dogs and cats should receive a single dose at 3 months of age or older. A repeat dose should be administered 1 year later.
3. Revaccination: Annual revaccination with a single dose is recommended.
1. Kaplan M.M., Koprowski H.: Rabies, Austr Vet Pract 10:208-215, 1980.
2. Uhaa I.J., Mandell E.J., Whiteway R., et al: Rabies surveillance in the United States during 1990. Am J. Vet Med 200:920-929, 1992.
FOR ANIMAL USE ONLY
Manufactured by: Zoetis Inc., Kalamazoo, MI 49007, USA
U.S. Vet Lic. No. 190
Distributed by: Intervet Inc., Omaha, NE 68103 USA
U.S. Vet Lic. No. 165A
1 800 224-5318 (USA)
5x10 mL Vials of Vaccine
2 GIRALDA FARMS, MADISON, NJ, 07940
|Technical Service (Companion Animal):||800-224-5318|
|Technical Service (Livestock):||800-211-3573|
|Every effort has been made to ensure the accuracy of the Nobivac 1-Rabies information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-05-31